Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Kuaishou Stock Jumps on Kling AI IPO Plans and $20 Billion Valuation 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Why the future of marijuana legalization remains hazy despite high public support 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
